Educational Symposium

The Vitamin D Debate in CKD and SHPT: How High Should We Aim?

November 08, 2019 | 12:45 PM - 01:45 PM

Location: TBD 4, Marriott Marquis

Session Description

Vitamin D therapy is commonly prescribed for patients with CKD and secondary hyperparathyroidism (SHPT). However, despite decades of vitamin D use, there remains a lack of consensus in important areas of clinical practice regarding therapeutic goals for 25-hydroxyvitamin D in patients with CKD with SHPT and vitamin D insufficiency. Using current therapies and emerging alternatives, speakers debate the appropriate target level for 25-hydroxyvitamin D for these patients.

Support is provided by an educational grant from OPKO Pharmaceuticals, LLC.

Learning Objective(s)

  • Describe the current clinical practice guideline target for 25-hydroxyvitamin D in healthy people as well as patients with CKD
  • Debate what level of 25-hydroxyvitamin D should be considered optimal for patients with CKD and ESKD

Learning Pathway(s)

  • Bone and Mineral Metabolism

Moderator

  • Michal L. Melamed, MD

Presentations

  • Introduction
    12:45 PM - 12:55 PM
  • Higher 25-Hydroxyvitamin D Targets Are Better for Patients with Kidney Disease
    12:55 PM - 01:15 PM
    James B. Wetmore, MD, MS
  • Lower 25-Hydroxyvitamin D Targets Are Better for Patients with Kidney Disease
    01:15 PM - 01:35 PM
    Julia J. Scialla, MD, FASN
  • Questions and Answers
    01:35 PM - 01:45 PM